189 related articles for article (PubMed ID: 8692580)
1. Whither the roles of rifater and rifamate?
McConville JH
Pa Med; 1996 Mar; 99(3):24-5. PubMed ID: 8692580
[No Abstract] [Full Text] [Related]
2. Anti-tuberculosis 4FDC tablets--mystery to chemistry.
Dekker TG; Lötter AP
Int J Tuberc Lung Dis; 2003 Mar; 7(3):205-6. PubMed ID: 12661831
[No Abstract] [Full Text] [Related]
3. Evaluation of the 3-drug combination, Rifater, versus 4-drug therapy in the ambulatory treatment of tuberculosis in Cape Town.
Macnab MF; Bohmer PD; Seager JR
S Afr Med J; 1994 Jun; 84(6):325-8. PubMed ID: 7740377
[TBL] [Abstract][Full Text] [Related]
4. New TB drug approved.
AIDS Patient Care; 1995 Feb; 9(1):42. PubMed ID: 11361363
[No Abstract] [Full Text] [Related]
5. Good news and not such good news.
Iseman MD
Int J Tuberc Lung Dis; 1999 Feb; 3(2):87. PubMed ID: 10091871
[No Abstract] [Full Text] [Related]
6. Three-in-one TB drug approved.
Posit Aware; 1995; ():5. PubMed ID: 11362378
[TBL] [Abstract][Full Text] [Related]
7. [Primary tuberculosis of the tongue].
Benmansour N; El hord S; Oudidi A; Benjelloun MC; El alami MN
J Otolaryngol Head Neck Surg; 2009 Apr; 38(2):E73-5. PubMed ID: 19442360
[No Abstract] [Full Text] [Related]
8. Treating tuberculosis with one combination drug.
Macnab MF; Seager JR
S Afr Med J; 1994 Aug; 84(8 Pt 1):507-8. PubMed ID: 7825089
[No Abstract] [Full Text] [Related]
9. Pharmaceutical formulation of a fixed-dose anti-tuberculosis combination.
Danckwerts MP; Ebrahim S; Pillay V
Int J Tuberc Lung Dis; 2003 Mar; 7(3):289-97. PubMed ID: 12661846
[TBL] [Abstract][Full Text] [Related]
10. Tuberculous meningitis.
Pozniak A
Int J STD AIDS; 1997 Feb; 8(2):139-40. PubMed ID: 9061416
[No Abstract] [Full Text] [Related]
11. Clinical practice. Latent tuberculosis infection.
Jasmer RM; Nahid P; Hopewell PC
N Engl J Med; 2002 Dec; 347(23):1860-6. PubMed ID: 12466511
[No Abstract] [Full Text] [Related]
12. Tuberculosis and renal transplantation.
Zaragoza RM; Hernandez A; Treviño M; Diliz HS; Alvarez L
Transplant Proc; 1996 Dec; 28(6):3309. PubMed ID: 8962285
[No Abstract] [Full Text] [Related]
13. Fixed-dose combination and therapeutic drug monitoring in tuberculosis: friend or foe?
Zuur MA; Akkerman OW; Davies Forsman L; Hu Y; Zheng R; Bruchfeld J; Tiberi S; Migliori GB; Alffenaar JC
Eur Respir J; 2016 Oct; 48(4):1230-1233. PubMed ID: 27587558
[No Abstract] [Full Text] [Related]
14. From the Food and Drug Administration.
Nightingale SL
JAMA; 1994 Aug; 272(5):344. PubMed ID: 8028152
[No Abstract] [Full Text] [Related]
15. Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a cost-effectiveness analysis based on a multicenter clinical trial.
Jasmer RM; Snyder DC; Saukkonen JJ; Hopewell PC; Bernardo J; King MD; Kawamura LM; Daley CL;
Clin Infect Dis; 2004 Feb; 38(3):363-9. PubMed ID: 14727206
[TBL] [Abstract][Full Text] [Related]
16. Drug combinations and the bioavailability of rifampicin.
Fox W
Tubercle; 1990 Dec; 71(4):241-5. PubMed ID: 2267677
[No Abstract] [Full Text] [Related]
17. [Antitubercular chemotherapy].
Jouveshomme S; Dautzenberg B
Rev Mal Respir; 1997 Dec; 14 Suppl 5():S88-104. PubMed ID: 9496594
[TBL] [Abstract][Full Text] [Related]
18. Safety of rifampin and pyrazinamide for the treatment of latent tuberculosis infection.
Stout JE
Expert Opin Drug Saf; 2004 May; 3(3):187-98. PubMed ID: 15155147
[TBL] [Abstract][Full Text] [Related]
19. [Tuberculosis of the middle ear: a rare extrapulmonary manifestation].
Schütte W; Berghaus A; Schütte A
Dtsch Med Wochenschr; 1996 Dec; 121(49):1551. PubMed ID: 8998926
[No Abstract] [Full Text] [Related]
20. [Experimental evidence for Mycobacterium tuberculosis persistence in M. tuberculosis-infected H37RV mice in the treatment with 3 first-line drugs (rifampicin, isoniazid, pyrazinamide)].
Smirnova TG; Chernousova LN; Andreevskaia SN; Nikolaeva GM
Probl Tuberk Bolezn Legk; 2004; (3):32-7. PubMed ID: 15338898
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
